ConductScience.org, home

Library / Genes

NCAM1: neural cell adhesion molecule 1

1 protein, 85 patents, 2 drugs, 6 trials, 13,651 NIH grants and 46,124 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolNCAM1HGNC
Nameneural cell adhesion molecule 1HGNC
NCBI Gene ID4684NCBI Gene
HGNC IDHGNC:7656HGNC
EnsemblENSG00000149294NCBI Gene
AliasesCD56, MSK39, NCAMNCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P13591Neural cell adhesion molecule 18587Ensembl, GeneID, HGNCUniProt

Patents 85

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
JP 2025172069 A2025-11-20401P13591Espacenet
EP 4650780 A22025-11-195193P13591Espacenet
EP 4641201 A22025-10-294777P13591Espacenet
EP 4641202 A22025-10-29277P13591Espacenet
EP 4641203 A22025-10-29162P13591Espacenet
JP 2025147176 A2025-10-069197P13591Espacenet
JP 2025529142 A2025-09-042780P13591Espacenet
JP 2025529142 A2025-09-047118P13591Espacenet
US 12371689 B22025-07-292780P13591Espacenet
US 12371689 B22025-07-297118P13591Espacenet

Drugs 2

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
LORVOTUZUMAB MERTANSINECHEMBL1743037Neural cell adhesion molecule 1 binding agentBINDING AGENTChEMBL
ONCOLYSIN SCHEMBL2109634Neural cell adhesion molecule 1 binding agentBINDING AGENTChEMBL

Trials 6

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT02452554LORVOTUZUMAB MERTANSINEPHASE22019-08-29ClinicalTrials.gov
NCT02420873LORVOTUZUMAB MERTANSINEPHASE22018-08-28ClinicalTrials.gov
NCT01237678LORVOTUZUMAB MERTANSINEPHASE1/PHASE22018-01-18ClinicalTrials.gov
NCT00991562LORVOTUZUMAB MERTANSINEPHASE1ClinicalTrials.gov
NCT00346255LORVOTUZUMAB MERTANSINEPHASE1ClinicalTrials.gov
NCT00065429LORVOTUZUMAB MERTANSINEPHASE1/PHASE22012-06-20ClinicalTrials.gov

NIH grants 13651

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA008748Cancer Center Support Grant2872,025NIH's project files
P30CA016672Cancer Center Support Grant2312,025NIH's project files
P01CA065493Off-the-Shelf Immune Effector Cells for Hematological Malignancies1002,025NIH's project files
P30CA016058Cancer Center Support Grant912,025NIH's project files
P01CA111412NK cells, their receptors and cancer therapy782,025NIH's project files
U19AI057229Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro642,025NIH's project files
P30CA077598Cancer Center Support Grant552,025NIH's project files
UL1TR001863Yale Clinical and Translational Science Award542,025NIH's project files
P30CA047904Cancer Center Support Grant482,025NIH's project files
P30CA021765Cancer Center Support Grant (CCSG)472,025NIH's project files

Papers 46124

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42824020PubTator, text miningPubMed
42819295PubTator, text miningPubMed
42818150PubTator, text miningPubMed
42814317PubTator, text miningPubMed
42813143PubTator, text miningPubMed
42808444PubTator, text miningPubMed
42807515PubTator, text miningPubMed
42802440PubTator, text miningPubMed
42802439PubTator, text miningPubMed
42800594PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license